Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden; Division of Molecular Medicine, Laboratory for Personalized Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden.
Cancer Lett. 2017 Oct 28;407:113-122. doi: 10.1016/j.canlet.2017.04.007. Epub 2017 Apr 12.
During the last decades, basic and translational research has enabled great improvements in the clinical management of cancer. However, scarcity of complete remission and many drug-induced toxicities are still a major problem in the clinics. Recently, microRNAs (miRNAs) have emerged as promising therapeutic targets due to their involvement in cancer development and progression. Their extraordinary regulatory potential, which enables regulation of entire signalling networks within the cells, makes them an interesting tool for the development of cancer therapeutics. In this review we will focus on miRNAs with experimentally proven therapeutic potential, and discuss recent advances in the technical development and clinical evaluation of miRNA-based therapeutic agents.
在过去的几十年中，基础和转化研究使得癌症的临床管理取得了重大进展。然而，完全缓解的稀缺和许多药物诱导的毒性仍然是临床中的一个主要问题。最近，microRNAs（miRNAs）作为有前途的治疗靶点出现，因为它们参与了癌症的发生和发展。它们非凡的调节潜力，能够在细胞内调节整个信号网络，使它们成为癌症治疗药物开发的一个有趣工具。在这篇综述中，我们将重点讨论具有实验证明的治疗潜力的 miRNAs，并讨论 miRNA 治疗剂的技术发展和临床评估的最新进展。
